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Abstract
European red deer (Cervus elaphus elaphus) are susceptible to the agent of bovine spongi-
form encephalopathy, one of the transmissible spongiform encephalopathies, when chal-
lenged intracerebrally but their susceptibility to alimentary challenge, the presumed natural
route of transmission, is unknown. To determine this, eighteen deer were challenged via
stomach tube with a large dose of the bovine spongiform encephalopathy agent and clinical
signs, gross and histological lesions, presence and distribution of abnormal prion protein
and the attack rate recorded. Only a single animal developed clinical disease, and this was
acute with both neurological and respiratory signs, at 1726 days post challenge although
there was significant (27.6%) weight loss in the preceding 141 days. The clinically affected
animal had histological lesions of vacuolation in the neuronal perikaryon and neuropil, typi-
cal of transmissible spongiform encephalopathies. Abnormal prion protein, the diagnostic
marker of transmissible encephalopathies, was primarily restricted to the central and periph-
eral nervous systems although a very small amount was present in tingible body macro-
phages in the lymphoid patches of the caecum and colon. Serial protein misfolding cyclical
amplification, an in vitro ultra-sensitive diagnostic technique, was positive for neurological
tissue from the single clinically diseased deer. All other alimentary challenged deer failed to
develop clinical disease and were negative for all other investigations. These findings show
that transmission of bovine spongiform encephalopathy to European red deer via the ali-
mentary route is possible but the transmission rate is low. Additionally, when deer carcases
are subjected to the same regulations that ruminants in Europe with respect to the removal
of specified offal from the human food chain, the zoonotic risk of bovine spongiform enceph-
alopathy, the cause of variant Creutzfeldt-Jakob disease, from consumption of venison is
probably very low.
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Introduction
Bovine spongiform encephalopathy (BSE) is infectious to, primarily, domestic cattle but also
wild bovids, several species of antelope, sheep and felids and is considered to be the cause of
variant Creutzfeldt-Jakob disease (vCJD) in humans [1,2]. It is a member of the transmissible
spongiform encephalopathies (TSE) group of diseases, also known as prion diseases, which in-
clude, amongst others, scrapie in sheep and goats, sporadic, familial and iatrogenic Creutz-
feldt-Jakob disease (CJD) and kuru in humans, transmissible mink encephalopathy in ranched
mink and chronic wasting disease (CWD) in farmed and free-living cervids [3]. All TSEs are
invariably fatal and are characterised by long incubation periods leading to clinical neurological
manifestations. The pathology is usually linked to the conversion of the normal host-encoded
membrane-bound prion protein (PrPC) to the abnormal disease-associated isoform (PrPd)
which accumulates in the nervous system and, depending on the host species and the TSE
agent involved, in the lymphoreticular system [4] and also some other viscera including kidney,
muscle and adrenal [5]. Definitive diagnosis of TSEs is, at present, dependent on the detection
of abnormal PrP in tissues by immunohistochemistry (PrPd) or of proteinase resistant abnor-
mal PrP (PrPres) by a variety of biochemical methods [6]. Susceptibility to natural, presumed
orally, acquired TSEs is influenced by the age at exposure and the dose of challenge and epide-
miological studies in cattle have suggested younger animals are more susceptible to BSE [7].
Additionally, oral BSE challenge of newborn sheep may be more efficient than sheep exposed
to oral BSE as adults [8,9]. Similarly, following scrapie exposure it has been shown experimen-
tally, with respect to both attack rate and incubation period, pre-weaned lambs are at greater
risk of infection, possibly due to patent gut epithelium [10].
Polymorphisms in the prion protein gene (PRNP) determine the degree of susceptibility
and resistance to TSEs in several species and also frequently influence the length of the incuba-
tion period [11]. Development of clinical disease in classical scrapie and BSE in sheep is pri-
marily associated with polymorphisms in three specific codons (136, 154 and 171) of the ovine
PRNP gene although other codons may play a role as well [12,13]. No such strong genetic asso-
ciation with susceptibility or resistance to BSE appears to exist for domestic cattle derived from
the Bos taurus lineage and most seem at risk (reviewed in [12]). However, in British and Ger-
man cattle herds more complex variations in the regulatory regions of the PRNP gene may play
a role in the control of susceptibility to BSE [14–17]. In humans, codon 129 is strongly influen-
tial for susceptibility to both sporadic and variant forms of CJD [18]. In deer, a total of 16 poly-
morphic codons within PRNP have been reported with a large number of PRNP alleles and
amino acid substitutions found in white-tailed deer (Odocoileus virginianus), European red
deer (Cervus elaphus elaphus), reindeer (Rangifer tarandus) and mule deer (Odocoileus hemio-
nus) [19]. A degree of genetically conferred resistance to CWD seems to occur in white-tailed
deer due to polymorphisms in codons 95 and 96 [20] and in mule deer due to a polymorphism
in codon 225 [21] but in neither case is full resistance conferred. No naturally occurring TSE
has been diagnosed in reindeer to date but the PRNP sequence suggest they would be suscepti-
ble to CWD [22] and recent experimental studies have proven this [23]. With respect to CWD
in Rocky mountain elk (wapiti, Cervus canadensis nelsoni) heterozygosity (methionine (M)/
leucine (L)) in codon 132 of PRNP, which is the equivalent position to human PRNP codon
129 [24], has been proposed to provide some protection [25] although this has been disputed
[26] and other studies suggest this polymorphism primarily alters the length of the incubation
period [27].
A PRNP polymorphism in codon 226 (glutamine (Q)/glutamate (E)) has been described for
European red deer and Sika deer (Cervus nippon) [28], but not yet for the Rocky mountain elk,
and the association of this amino acid change with TSE susceptibility has recently been
BSE in Red Deer
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demonstrated in transgenic mice [29]. Codon 226 glutamine is encoded in PRNP from mule
deer [30], white-tailed deer [20], moose (Alces alces), cattle, sheep, goats and nyala (Nyala
angasii) [12] whereas glutamate is encoded in PRNP from Rocky mountain elk, kudu
(Tragelaphus spp.) and cats all of which have shown natural susceptibility to the CWD or BSE
agent [12,31,32]. Retrospective analysis showed European red deer of all codon 226 PRNP
genotypes were susceptible to BSE when challenged by the intra-cerebral route [33] M.P.
Dagleish pers observation), which is important as they are consumed by humans so if natural
transmission takes place they are a potential source of vCJD. However, their susceptibility to
oral challenge, the accepted route of natural BSE transmission, is unknown.
The aim of this study was to assess the susceptibility of European red deer to oral challenge
with a bovine derived BSE brain homogenate to assess transmission by the presumed natural
route and therefore the potential risk of zoonotic transmission of BSE from red deer.
Materials and Methods
Animals, BSE inocula, challenge procedure and biopsies
Twenty-five European red deer were housed at 1–2 days old and hand reared with milk replacer
prior to weaning onto ad libitum hay and water and a weight dependant allocation of proprie-
tary concentrate feed. At 7–10 weeks of age, 18 animals (10 males and 8 females) were each
given 25g of a pool of BSE-positive bovine brain material (VLA-Weybridge SE1736 BBP1) [33]
diluted 1:4 (w/v) in 0.32M sucrose solution (total volume 100ml) via a stomach tube followed by
flushing of the stomach tube with 50ml of water. Unchallenged environmental controls (n = 7, 3
males and 4 females) were kept in separate but adjacent pens to the challenged deer. Animals
were examined daily for clinical signs and weighed at regular intervals. Animals were culled at
190 days post-challenge (dpc) (n = 6 BSE-challenged and 1 unchallenged control), 365 dpc (n =
6 BSE-challenged and 2 unchallenged controls) or allowed to progress until clinical signs or the
termination of the experiment at 2320 dpc (n = 6 BSE-challenged and 4 unchallenged controls)
(Table 1). Four biopsies were taken from the recto-anal mucosa-associated lymphoid tissue
(RAMALT) of the group allowed to progress until clinical signs/termination of the experiment
and evaluated for the presence of PrPd by immunohistochemistry (IHC, see below) at 511, 706,
855 and 1853 dpc. Biopsies were performed as described previously [34] with the addition of
reversible sedation (10mg/kg medetomidine hydrochloride, Domitor, Janssen Animal Health,
UK; atipamezole hydrochloride, Antisedan, Janssen Animal Health, UK). All experimental
procedures were approved by the Moredun Research Institute Animals Experiments Ethical
Committee and authorised under the UK Animals (Scientific Procedures) Act 1986.
Genotyping
Genotyping was performed as described previously [33], either from blood samples taken from
live deer into vacutainers containing EDTA (BD Bioscience, Erembodegem, Belgium) or from
frozen brain material collected post-mortem. Briefly, PCR amplification and sequencing were
performed as described previously [35], using amplification oligonucleotides DeerPrP-213d
(AGGTCAACTTTGTCCTTGGAGGAG) and DeerPrP+139u (TAAGCGCCAAGGGTATTA
GCAT) and sequencing oligonucleotides DeerPrP+70u (GCTGCAGGTAGATACTCCCTC)
and DeerPrP-86d (CAGTCATTCATTATGCTGCAGACT).
Post-mortem examination
All animals were subjected to full post-mortem examination after euthanasia by intra-venous
pentobarbitone after sedation as described above and an extensive range of tissue samples were
BSE in Red Deer
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taken, as described previously [33], and fixed in 10% neutral buffered formalin and/or stored at
−80°C. Fixed samples were post-fixed in fresh 10% neutral buffered formalin, processed for his-
tology routinely and then embedded in paraffin wax. Sections (4μm thick) were mounted on
glass slides (Superfrost slides, Menzel-Gläser, Braunschweig, Germany) and either stained with
haematoxylin and eosin (HE) or subjected to IHC for PrPd (see below).
Immunohistochemical localisation of PrPd
This was performed as described previously [33,36] using two primary antibodies to PrP which
have wide inter-species reactivity; F99, clone 97.6.1 (VMRD Inc., Pullman, USA), which binds
to amino acid sequence 220–225 of human PrP and BAR224 (CEA, Saclay, France) which rec-
ognizes amino acid sequence 141–147 of human PrP. Briefly, antigen retrieval included
Table 1. Summary of animal, immunohistochemical and serial protein misfolding cyclical ampliﬁcation data.
Deer
ID
Sex Challenge
status
DPC-
PME
Genotype (PrP gene,
codon 226)
IHC for
PrPd
sPMCA 1st Exp.
(3rd round)
sPMCA 2nd Exp.
(3rd round)
sPMCA 2nd Exp.
(4rd round)
322 M UNC 190 QQ N 0/4 0/4 0/4
319 M UNC 365 QE N - - -
334 M UNC 365 EE N 0/4 0/4 0/4
032 F UNC 2320 QQ N - - -
034 F UNC 2320 QE N - - -
039 F UNC 2320 EE N 1/4 0/4 0/4
014 F UNC 2320 EE N - - -
327 M BSE-C 190 QE N - - -
309 M BSE-C 190 EE N - - -
031 F BSE-C 190 QQ N - - -
320 M BSE-C 190 QE N - - -
324 M BSE-C 190 QQ N - - -
326 M BSE-C 190 QQ N - - -
323 M BSE-C 365 QE N 0/4 0/4 0/4
337 M BSE-C 365 EE N 0/4 0/4 0/4
314 M BSE-C 365 QQ N 0/4 0/4 0/4
318 M BSE-C 365 QE N - - -
310 M BSE-C 365 QE N - - -
028 F BSE-C 365 QQ N 0/4 0/4 0/4
009 F BSE-C 1727 QQ P 4/4 4/4 4/4
015 F BSE-C 2320 QE N 0/4 0/4 0/4
033 F BSE-C 2320 EE N 0/4 0/4 0/4
016 F BSE-C 2320 EE N 0/4 0/4 0/4
023 F BSE-C 2320 QE N 0/4 0/4 0/4
037 F BSE-C 2320 EE N 0/4 0/4 0/4
Deer identiﬁcation, sex, challenge status, time of post-mortem examination, genotype at codon 226 of prion protein gene, presence of abnormal protein by
immunohistochemistry (PrPd) and western blotting (PrPres) by western blotting after different experiments of serial protein misfolding cyclic ampliﬁcation
(sPMCA). The animal positive for abnormal prion protein is deer 009 and this was by both IHC and sPMCA. Note that for sPMCA a value of 1/4 is
considered negative and probably due to contamination of the sample in this exceptionally sensitive technique. DPC-PME = days post challenge of post
mortem examination, PrP = prion protein, PrPd/PrPres = abnormal prion protein, IHC = immunohistochemistry, sPMCA = serial protein misfolding cyclic
ampliﬁcation, Exp. = experiment, M = male, F = female, UNC = unchallenged negative control, BSE-C = BSE oral challenged, Q = glutamine, E = glutamic
acid, N = negative, P = positive, for sPMCA x/x = number of PrPres positive tubes/number of replicates, – = not examined by sPMCA.
doi:10.1371/journal.pone.0116094.t001
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immersion in 98% formic acid for 5 minutes followed by autoclaving for 30 minutes at 121°C
in 0.2% citrate buffer pH6.0. After blocking steps to quench endogenous peroxidase activity
and to block reactivity of non-specific tissue antigens, incubation with the primary antibody
was carried out overnight at 27°C. The subsequent steps of the immunohistochemical
protocol to visualise the bound primary antibodies were performed using a commercial
immunoperoxidase technique (Vector-elite ABC kit, goat anti-mouse IgG and DAB
chromagen, all Vector Laboratories, Peterborough, UK) at the end of which sections were
immersed in 0.5% copper sulphate to enhance immunoperoxidase colour reaction and finally
counterstained with Mayer’s haematoxylin.
Ovine BSE shows reduced patterns of intracellular labelling with antibodies that recognise
the extreme N-terminus of PrP and that are characteristically different from most scrapie
sources [5]. To confirm the BSE nature of the infection, serial sections of selected brain areas
were incubated with the N-terminal 12B2 monoclonal antibody (kindly provided by Jan
Langeveld, Central Institute for Animal Disease Control, Netherlands), which recognizes
amino acid sequence 93–97 of ovine PrP [37], and subjected to the same IHC protocol as
described above.
Protein Misfolding Cyclic Amplification (PMCA)
Serial rounds of PMCA were performed as described previously [38]. Briefly, 50μl of cattle
brain homogenate, confirmed to be BSE negative, was supplemented with 0,5% sulfated dex-
tran (Mr ~70,000) from Leuconostoc spp. (Sigma-Aldrich) and seeded with 5μl of red deer
brain samples (10% brain homogenate in phosphate buffered saline) from 13 of the animals
(n = 6 BSE challenged animals that either developed clinical signs or were culled at the end of
the experiment at 2320 dpc, n = 4 culled at 365 dpc and n = 3 environmental controls also
culled at the end of the experiment at 2320 dpc). To ensure bovine brain homogenate was a
suitable substrate for European red deer samples with respect to serial PMCA (sPMCA) an ini-
tial titration (10−1 to 10−11) was performed using red deer brain material that was known to be
positive for PrPd by IHC (deer ID 009, see below).
All 13 red deer brain samples (in quadruplicate) were subjected to two independent experi-
ments of sPMCA. All resultant samples were analysed for PrPres (proteinase resistant PrP
which is another disease associated form of PrPC) by western blotting using monoclonal anti-
body 2A11 diluted 1:2000 [39]; for the first experiment after round 3 and for the second experi-
ment after rounds 3 and 4. Unseeded tubes (n = 4) containing only the BSE negative cattle
brain homogenate were included as a negative control preparation.
Results
Clinical signs
None of the animals subjected to post-mortem examinations at either 190 or 365 dpc showed
any clinical signs of disease. Of the six remaining BSE challenged deer, a single animal (ID 009,
female) developed acute clinical signs at 1726 dpc. These included fear of people (prior to this
the animal was very tame and actively approached people in the pen), restlessness, pacing,
stereotypic head movements and low head carriage, abnormal flicking of the ears, laboured
and audible mouth breathing and ptyalism. The animal was euthanased the following day
(1727 dpc) on welfare grounds and subjected to full post-mortem examination. At post-
mortem examination the animal weighed 57.6 Kg and had lost 27.6% (21.9 Kg) of its body
weight compared to its peak weight of 79.5 Kg recorded at 1586 dpc. None of the five remain-
ing BSE challenged deer, nor any of the negative control animals, developed clinical signs or
BSE in Red Deer
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weight loss, other than small seasonal variations, by the termination of the experiment at day
2320 dpc.
Genotype
All animals were genotyped at polymorphic codons 132 and 226 of PRNP, other amino acid
changes were not deduced from the gene sequences. All deer in the study were homozygous for
methionine at codon 132 whereas they were of mixed genotypes at codon 226 (Table 1). The
only animal which developed clinical disease was homozygous for glutamine (QQ) at codon
226 and this was the only animal of that genotype in the BSE-challenged group of longest dura-
tion which was comprised of six deer allowed to progress to clinical signs or termination of the
experiment (Table 1).
Histological lesions and immunohistochemical labelling of PrPd
PrPd was not detected by IHC within any of the RAMALT biopsy samples from any of the deer
over the whole course of the experiment.
Microscopical examination of HE stained sections of brain from the single clinically affected
deer (ID 009) revealed widespread spongiform change with vacuolation seen in the neuronal
perikaryon and neuropil of the brainstem (Fig. 1A), the molecular layer of the cerebellum
(Fig. 1B) and thalamus (Fig. 1C). No such lesions were observed in any of the other 24 deer ei-
ther BSE-challenged or unchallenged controls and no significant lesions were present in any of
the other tissues examined.
Immunohistochemically PrPd was found in the clinically affected deer (ID 009) only and
was largely restricted to the central and peripheral nervous systems (CNS and PNS respective-
ly). Antibodies F99 and BAR224 were both equally effective at labelling PrPd in deer tissue with
no discernible differences. In the CNS, PrPd accumulated predominantly in the brainstem and
cerebellum with widespread diffuse particulate labelling of the neuropil and conspicuous intra-
neuronal accumulation (Fig. 2). Peri-neuronal labelling was prominent in the dorsal motor nu-
cleus of the vagus nerve (DMNV) and in the striatum. Intraneuronal granular accumulations
were prominent in nuclei of the medulla, such as the accessory cuneate, spinal trigeminal
(Fig. 2A) and posterior olivary nucleus (Fig. 2B), but were also present elsewhere in the brain
with the exception of the Purkinje cells of the cerebellum. Intraneuronal PrPd aggregates were
greatly diminished or even absent when serial sections were incubated with the PrP N-terminal
12B2 antibody (Fig. 2C & 2D). Such a marked decrease in intracellular signal with preservation
of the extracellular signal following labelling with PrP N-terminal specific antibodies is a con-
sistent feature of BSE infections in several other species [5]. PrPd was also detected in all seg-
ments of the spinal cord, in autonomic ganglia, cranial and peripheral nerves (Fig. 3A), sensory
retina (Fig. 3B) and ganglion cells (myenteric plexus) throughout the enteric nervous system
(Fig. 3C) which were frequently in close proximity to nearby lymphoid follicles, the majority of
which were negative. However, sparse deposits of PrPd were also detected within tingible body
macrophages in a very small number of the lymphoid follicles within the caecum (Fig. 4A) and
colon (Fig. 4B) but not in any other lymphoid tissue examined. All other organs examined in-
cluding skin, cardiac and skeletal muscles, lung, liver, rumen, abomasum, small intestine, kid-
ney, pancreas and mammary gland were negative for PrPd.
Protein Misfolding Cyclic Amplification
The initial titration to determine the suitability of bovine brain homogenate for sPMCA with a
European red deer brain sample (the single clinically positive animal, ID009) gave a positive
BSE in Red Deer
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result down to a sample dilution of 10−11 after 3 rounds of sPMCA (Fig. 5) confirming its suit-
ability for use in this study.
All European red deer brain samples for both independant experiments of sPMCA from the
single clinically positive animal (ID 009) were consistently positive for PrPres in quadruplicate
at all rounds examined (third round in the first experiment and third and fourth rounds in the
second experiment, Table 1 and Fig. 6). All the rest of the samples were negative except a single
tube of one of the quadruplicate samples in the third round from experiment one from a nega-
tive control animal (039) but which was negative in all rounds throughout experiment two (see
Table 1).
Discussion
This investigation resulted in the first and only known case, to date, of clinical disease or accu-
mulation of abnormal PrPd in any cervid species due to oral challenge with BSE. The increase
in incubation period compared to European red deer challenged with BSE intra-cerebrally
(1060 days) [33] compared to oral challenge (1727 days) is approximately 60% and similar to
the differences observed in incubation periods for sheep or goats when challenged with TSE
agents by these two routes [40,41]. The neurological clinical signs observed could be broadly
related to the spongiform encephalopathy and the accumulation of PrPd in that the restless-
ness, stereotypic head movements and pacing may be due to compromise of the nucleus
accumbens [42], found in the striatum, and the laboured breathing due to the lesions in the
medulla, where the respiratory centre is located [43]. Alternatively, the laboured and audible
mouth breathing may have been due to, or contributed to by, compromise of either of the re-
current laryngeal nerves resulting in some degree of laryngeal paralysis but we were unable to
determine this. Apart from the gradual loss of body weight, the speed of onset of clinical signs
and progression was very rapid but animal welfare requirements precluded any further longitu-
dinal study of these. The clinical signs described for this animal are broadly similar to those re-
ported for clinical BSE in European red deer challenged via the intracerebral route [33], clinical
cases of CWD in deer [44] and clinical cases of BSE in cattle [45].
The predominant hindbrain vacuolation pattern in this clinically affected European red
deer challenged orally with BSE was similar to the same species challenged intra-cerebrally
with the same BSE inoculum [33], cattle naturally infected with BSE [46], sheep challenged
orally with the BSE agent [41] and deer and elk naturally infected with CWD [47]. Additional-
ly, the tissue distribution of PrPd in the clinically affected European red deer, which was re-
stricted primarily to the central and peripheral nervous systems, was similar to that seen in the
same species challenged intracerebrally with the same BSE inoculum [33]. However, this was
in contrast to deer and elk naturally infected with CWD [44] and sheep naturally [48] or exper-
imentally challenged via the oral route with scrapie [5] or BSE [41] which all have extensive pe-
ripheral accumulation of PrPd in the lymphoid tissues and supports the body of work that
states that both the host species and the TSE agent both play roles in determining the pattern
of accumulation of PrPd [4,5]. The PrPd labelling in the brain of the clinically affected Europe-
an red deer was predominantly punctate and granular and this pattern, along with the sites
listed, is typical of accumulations in the brains of other ruminant sources of BSE infection [41].
The presence of PrPd in a small number of tingible body macrophages in gut-associated
lymphoid follicles in the clinically affected European red deer was not present when the same
Figure 1. Vacuolation of neuronal perikarya and neuropil in the dorsal motor nucleus of the vagus
nerve (DMNV) in the medulla oblongata (a), the molecular layer of the cerebellum (b) and the thalamus
(c) of the only clinically affected deer (ID 009). HE, x200.
doi:10.1371/journal.pone.0116094.g001
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species was challenged by the intracerebral route with the same inoculum [33]. The mechanism
of spread of accumulation of PrPd in the intracerebrally challenged European red deer was
probably incubation-period related centrifugal spread from the brain to the spinal column, cra-
nial and other peripheral nerves [33]. This is thought also to be the major mechanism of dis-
semination in cattle infected by the oral route with the BSE agent after initial haematogenous
spread from the intestine to the brain [49]. Studies have examined, in detail, the anatomy of
initial translocation of both the BSE [50] and scrapie [10] agents across the intestinal mucosal
barrier of sheep and concluded that the villous lacteals of the lamina propria and submucosal
lymphatics are the key route in the first two to three and a half hours of exposure. PrPd was not
found in draining lymph nodes until 24 hours post-challenge and not before 30 days in Peyer’s
patches [10] suggesting that the lymph node accumulation was probably residual inoculum
and that in the Peyer’s patches was probably de novo PrPd. As PrPd was detected only in the
lymphoid tissue of the clinically affected European red deer challenged orally with BSE after an
incubation period of 1727 days, and then only in very small amounts, and not those examined
at 180 and 360 dpc nor those challenged intracerebrally which were sampled at 794–1290 dpc
[33] it would appear that this is de novo PrPd rather than residual inoculum. This being the
case, European red deer challenged orally with BSE appear very similar to cattle with respect to
organ distribution of PrPd [51,52]. These findings further support the belief that the accumula-
tion and distribution of PrPd are influenced by a combination of the TSE agent and the host
species [4,5].
The only animal to develop clinical disease in this study was homozygous for glutamine at
PRNP codon 226 and, unfortunately, this was the only animal of this genotype in the group al-
lowed to progress to clinical disease or termination of the experiment (Table 1). At the com-
mencement of this study the only known genetic variation in the PRNP of cervid species
closely related to European red deer and known to influence TSE susceptibility was codon 132
in elk where heterozygosity (methionine/leucine) was thought to confer a degree of resistance/
lengthening of the incubation period in CWD infections [25–27]. This was supported by
codon 132 in elk being the equivalent of human PRNP codon 129 which is highly influential in
susceptibility to both sporadic and variant CJD [18,53]. Therefore, the European red deer in
this study were initially subjected to evaluation of PRNP codon 132 only and as all were homo-
zygous for methionine they were randomly assigned to the four experimental groups (6 month
cull, 12 month cull, progression to clinical signs/termination of experiment and unchallenged
negative control). At a later date it was shown that codon 226 of deer PRNP contained a poly-
morphism [28] that may be associated with TSE susceptibility [29] hence this was determined
retrospectively after the animals had been assigned to their groups and already challenged with
the BSE agent. Although it is tempting to speculate that European red deer homozygous for
glutamine at PRNP codon 226 may be genetically more susceptible to BSE by the oral route
than deer carrying glutamate at codon 226, one clinical animal cannot be statistically sufficient
to make this association and further trials are required. Similar problems have been encoun-
tered in other long-term TSE studies where variations in previously unexamined PRNP codons
have subsequently been shown to significantly affect the clinical disease outcome [11]. The
Figure 2. Accumulation of PrPd (brown pigment) in the brain of the only clinically affected deer (ID
009).Diffuse particulate and punctate intraneuronal PrPd in the spinal tract nucleus of the trigeminal nerve (a)
and inferior olivary nucleus (b); IHC with antibody F99, clone 97.6.1 x200. (c) Diffuse particulate, peri-
neuronal and punctate intraneuronal PrPd in the dorsal motor nucleus of the vagus nerve with antibody F99,
clone 97.6.1 (x200). Only the diffuse particulate and peri-neuronal PrPd types remain within the dorsal motor
nucleus of the vagus nerve while the punctate intraneuronal PrPd type is unlabelled after incubation with the
PrP N-terminal specific 12B2 antibody (d; x200).
doi:10.1371/journal.pone.0116094.g002
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Figure 3. Accumulation of PrPd (brown pigment) in the sympathetic chain ganglion cells (a), the
plexiform layers of the retina (b) andmyenteric plexus (c) of the single clinically affected deer (ID 009).
IHC with antibody Bar224, x200.
doi:10.1371/journal.pone.0116094.g003
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Figure 4. Accumulation of PrPd (brown pigment) in tingible bodymacrophages present in the
lymphoid follicles of the caecum (a) and colon (b) of the only clinically affected deer (ID 009). IHC with
antibody Bar224, x200.
doi:10.1371/journal.pone.0116094.g004
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only published assessments of the frequency of the various genotypes of PRNP codon 226 for
European red deer were from those in Scotland were the QQ genotype was found in only
12.9% of animals over the whole country compared to 50% which were EE and 37.1% EQ [28].
However, one well studied island population within Scotland, which has no exchange with the
mainland, had a prevalence for the QQ genotype of only 6.0% and the whole study examined
Figure 5. Western immnoblot for PrPres, usingmonoclonal antibody 2A11, of brain homogenate from initial titration experiment to determine the
feasibility and sensitivity of serial protein misfolding cyclical amplification (sPMCA) using cattle brain homogenate for the detection of BSE agent
in tissues from European red deer. Brain tissue from the single European red deer that developed clinical signs (009) used. Note the presence of PrPres at
a dilution of 10−11 after only three rounds of sPMCA showing exceptional sensitivity and complete lack of PrPres in negative control samples showing lack of
spontaneous conversion of PrPC to PrPres. Dil = dilution, PK = proteinase-K treated (+) or not (−), MW =molecular weight markers.
doi:10.1371/journal.pone.0116094.g005
Figure 6. Western immunoblot for PrPres, usingmonoclonal antibody 2A11, of brain homogenates from orally challenged European red deer (n =
10) and unchallenged negative controls (n = 3) subjected to serial protein misfolding cyclical amplification (sPMCA), experiment two, round four.
Note PrPres is present only in brain homogenate from deer 009, the only animal that developed clinical signs which appeared at 1726 days after oral
challenge with BSE, and the positive control samples (BSE positive bovine, scrapie positive ovine and chronic wasting disease (CWD) positive cervine brain
homogenates). PME = post-mortem examination, dpc = days post-challenge, Neg Control = negative control, ID = deer identification number, PK =
proteinase-K treated (+) or not (−), MW =molecular weight markers, KD = kilo Daltons.
doi:10.1371/journal.pone.0116094.g006
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132 animals only [28]. If this study is representative of the European red deer population then
the prevalence of the PRNP codon 226 QQ genotype is the lowest.
The presence of possible infectivity in both the single clinically affected animal and the non-
clinically affected animals would have ideally been assessed by subjecting the resultant Europe-
an red deer brain material to in vivo infectivity studies in a rodent model of shorter incubation
period and/or further passage in European red deer but this was out-with the scope of this
study. Fortunately, sPMCA was available and due to its exceptionally high sensitivity it has
been proposed as a credible replacement for bioassay [54]. Our initial trials using bovine brain
tissue as a substrate for detecting BSE by sPMCA showed that it was highly suitable for testing
tissue from European red deer being able to detect a positive result to a sample dilution of
10−11 and, therefore, would probably be suitable for testing other closely related deer species, if
not all cervid species. The consistent presence of PrPres in 4/4 tubes at all rounds in both exper-
iments of sPMCA is strongly suggestive that infectivity was present in the single clinically af-
fected European red deer. The single positive tube, one of four replicates, from a negative
control animal (039) in round three of the first experiment of sPMCA was considered negative
and to be due to contamination of the sample at some point as all subsequent rounds from this
animal in experiment two were negative for PrPres. Additionally, as all replicates at all rounds
of the unseeded BSE negative bovine brain homogenate were negative it is unlikely this was a
stochastic event.
The results of this study show that alimentary transmission of BSE to European red deer is
possible but the transmission rate is low. However, culling of red deer in the UK, particularly
males, occurs mostly when they are 8–10 years (2920–3650 days) old and therefore well within
the possible incubation period for BSE [55]. Altogether our data suggest that when deer car-
cases for human consumption are subjected to the same regulations as other ruminant carcases
(The Specified Bovine Offal Order 1990 [56] and its amendments) the zoonotic risk of BSE
from consuming muscle from European red deer is probably very low.
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